title: A phase II trial of combined chemotherapy and surgery in stage IIIA non-small cell lung cancer.
abstract: A poor prognosis for patients with Stage IIIA clinical N2 treated by surgery alone has led clinical researchers to find a new treatment modality to improve the curative potential of surgery. Many Phas II trials have been carried out with induction chemo- or chemo-radiotherapy prior to surgery. From June 1988 to July 1991, 46 patients with non-small cell lung cancer (NSCLC) Stage IIIA clinical N2 entered a Phase II induction-chemotherapy trial. Patients received 2-3 cycles of high-dose cisplatin and etoposide. Forty-five were evaluable for response; the response rate was 82% (37/45: 3 CR, 34 PR). Toxicity was primarily hematologic. Surgical resection was performed in 35 patients; radical resection was possible in 28 patients (62%); three patients were incompletely resected and two patients were only explored. Three deaths were surgery-related. Median survival was 24.5 months with a 2-year survival of 53%. Cisplatin with etoposide is an active and safe induction chemotherapy regimen for NSCLC Stage IIIA N2 with a high response rate. The median survival seems to be prolonged and therefore, randomized trials are needed to compare this approach with other treatment modalities.
authors.affiliation: Department of Medical Oncology, Policlinico, Perugia, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Darwish
authors.forename: V
authors.initials: V
authors.lastname: Minotti
authors.forename: L
authors.initials: L
authors.lastname: Crinò
authors.forename: R
authors.initials: R
authors.lastname: Rossetti
authors.forename: P
authors.initials: P
authors.lastname: Fiaschini
authors.forename: E
authors.initials: E
authors.lastname: Maranzano
authors.forename: F
authors.initials: F
authors.lastname: Checcaglini
authors.forename: T
authors.initials: T
authors.lastname: Todisco
authors.forename: M
authors.initials: M
authors.lastname: Giansanti
authors.forename: U
authors.initials: U
authors.lastname: Mercati
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D005047:Etoposide; D002945:Cisplatin